Columbia Partners L.L.C. Investment Management reduced its stake in STAAR Surgical (NASDAQ:STAA) by 1.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 112,075 shares of the medical instruments supplier’s stock after selling 1,829 shares during the quarter. STAAR Surgical comprises 1.4% of Columbia Partners L.L.C. Investment Management’s holdings, making the stock its 20th largest position. Columbia Partners L.L.C. Investment Management owned 0.25% of STAAR Surgical worth $5,379,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently added to or reduced their stakes in the company. Winslow Evans & Crocker Inc. bought a new position in STAAR Surgical in the 3rd quarter valued at about $142,000. Engineers Gate Manager LP bought a new position in shares of STAAR Surgical during the second quarter worth approximately $208,000. Tower Research Capital LLC TRC increased its holdings in shares of STAAR Surgical by 367.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,877 shares of the medical instruments supplier’s stock worth $213,000 after purchasing an additional 5,405 shares during the period. Alambic Investment Management L.P. bought a new position in shares of STAAR Surgical during the second quarter worth approximately $214,000. Finally, Harvest Fund Management Co. Ltd bought a new position in shares of STAAR Surgical during the third quarter worth approximately $222,000. 84.11% of the stock is currently owned by hedge funds and other institutional investors.
Shares of STAA opened at $38.01 on Monday. STAAR Surgical has a 12 month low of $13.60 and a 12 month high of $54.00. The company has a market cap of $1.68 billion, a PE ratio of 3,801.00 and a beta of 2.05. The company has a current ratio of 5.35, a quick ratio of 4.76 and a debt-to-equity ratio of 0.01.
Several brokerages have recently commented on STAA. Zacks Investment Research raised shares of STAAR Surgical from a “hold” rating to a “strong-buy” rating and set a $51.00 target price on the stock in a report on Thursday, November 8th. BidaskClub cut shares of STAAR Surgical from a “buy” rating to a “hold” rating in a report on Monday, November 26th. Benchmark began coverage on shares of STAAR Surgical in a report on Monday, August 6th. They set a “buy” rating and a $45.00 target price on the stock. Finally, Canaccord Genuity raised their target price on shares of STAAR Surgical from $43.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, September 14th. One research analyst has rated the stock with a hold rating, four have assigned a buy rating and two have issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $45.25.
STAAR Surgical Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and delivery systems to deliver the lenses into the eye. The company provides Visian implantable collamer lenses (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
Further Reading: Stock Split
Want to see what other hedge funds are holding STAA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for STAAR Surgical (NASDAQ:STAA).
Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.